BackSteminent Biotherapeutics Overview

Steminent Biotherapeutics Accounts Payable

Track Steminent Biotherapeutics's accounts payable ($3.9M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$3.91M

Peer trimmed avg / median

Loading

Steminent Biotherapeutics Accounts Payable History

Loading

Steminent Biotherapeutics vs. peers: Accounts Payable Comparison

Loading

Steminent Biotherapeutics Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Steminent Biotherapeutics (7729.TWO) FAQ

Steminent Biotherapeutics posts a accounts payable of $3.9M as of September 2026. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Accounts Payable is one piece of Steminent Biotherapeutics's financial statement story. At $3.9M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 7729.TWO's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Steminent Biotherapeutics's other metric pages and overview cover the third.

Judging Steminent Biotherapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in accounts payable easier to interpret. Start with $3.9M here, then scan peer and history charts to see if the gap is persistent.